-The Indian Express April 1 marked the third anniversary of the passage of the Right of Children for Free and Compulsory Education (RTE). There is little argument that the implementation of the RTE in these three years has been less than satisfactory. Deadlines for the enforcement of input norms - infrastructure, pupil-teacher ratios - have come and gone and potentially game-changing provisions, like 25 per cent reservation for economically weaker sections...

-The Hindu   Rs. 4.7 cr. utilised last fiscal compared to Rs. 9 cr. in 2010-11 Bangalore: In what could be read as an MLA report card in a way, the performance of a large number of the State's Assembly constituencies, gauged under the national rural job guarantee schemes, progressively fell on many fronts during 2009-12. According to data pertaining to projects taken up under the Mahatma Gandhi Rural Employment Guarantee Act (MNREGA) for...

-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...

-The Hindustan Times Cancer drugs will cost almost 25% less if the regulator implements a new formula that calls for a price cap. The price regulator National Pharmaceutical Pricing Authority (NPPA) is considering a pricing mechanism similar to the one for insulin products - which has brought down prices by up to 40% - for 33 cancer drugs, most of them generics. Basically, the lowest price from the list of drugs in a...

-The Hindu The Supreme Court has denied Novartis a patent for its anti-cancer drug Gleevec. This leaves the door open for Indian pharmaceutical companies to produce their own versions of the drug. Since these are sold at roughly one tenth of the patented brand price, for thousands of cancer patients it means the difference between medicine and no medicine at all. It is not just cancer patients that will benefit, but...